Cancer Drug Design and Discovery

Informationen zum Autor Stephen Neidle is an Emeritus Professor of Chemical Biology at University College London, where he has also been the Director of Research in the School of Pharmacy. He has published over 500 primary papers and reviews and is a principal inventor on 14 patent filings. He has also written and edited several books on nucleic acids and anti-cancer drugs. Klappentext Using Information to Develop a Culture of Customer Centricity sets the stage for understanding the holistic marriage of information, socialization, and process change necessary for transitioning an organization to customer centricity. The book begins with an overview list of 8-10 precepts associated with a business-focused view of the knowledge necessary for developing customer-oriented business processes that lead to excellent customer experiences resulting in increased revenues. Each chapter delves into each precept in more detail.Focuses on the underlying principles for the design and subsequent development of new anticancer small molecule agents. This book includes several sections on the basic and applied science of cancer drug discovery and features those drugs that are approved for human use and are in the marketplace, as well as those that are still under development. Inhaltsverzeichnis Introduction - Stephen Neidle Foreword - Hilary Calvert Part I. Basic Principles and methodology Modern cancer drug discovery: integrating targets, technologies and treatments - Paul Workman and Ian Collins Pharmacogenomics and personalised medicines in cancer treatment - Wei-Peng Yong, Ross Soo and Federico Innocenti Structural biology and anticancer drug design - Puja Pathuri, David Norton, Henriette Willems, Dominic Tisi and Harren Jhoti Part II. Drugs in the laboratory and clinic Temozolomide: from cytotoxic to molecularly-targeted agent - Malcolm Stevens Temozolomide: patents and the perils of invention - Malcolm Stevens A new generation of cell-targeted drugs for cancer treatment - Paola B. Arimondo, Nicolas Guilbaud and Christian Bailly Inhibition of DNA repair as a therapeutic target - Stephany Veuger and Nicola J Curtin Inhibitors of tumour angiogenesis - Adrian L. Harris and Daniele G Generali The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer - Qingzhong Hu and Rolf W. Hartmann Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting - Zahid H Siddik Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel anticancer agents - Ian R Hardcastle Targeting altered metabolism - emerging cancer therapeutic strategy - Minsuh Seo, Robert Blake Crochet and Yong-Hwan Lee Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway - William A Denny and Gordon W. Rewcastle Antibody-drug conjugates delivering DNA cytotoxics - John A Hartley Inhibition of telomerase: promise, progress and potential pitfalls - Christopher G. Tomlinson, Scott B. Cohen and Tracy M. Bryan Targeting B-RAF: the discovery and development of B-RAF inhibitors - Phillip A Harris Part III. The reality of cancer drugs in the clinic Failure Modes in Anticancer Drug Discovery and Development - Richard A. Walgren and Christopher. A. Slapak Anticancer drug registration and regulation: current challenges and possible solutions - David Taylor, Erling Donnelly and Silvia Chioato ...

Autorentext
Stephen Neidle is an Emeritus Professor of Chemical Biology at University College London, where he has also been the Director of Research in the School of Pharmacy. He has published over 500 primary papers and reviews and is a principal inventor on 14 patent filings. He has also written and edited several books on nucleic acids and anti-cancer drugs.

Klappentext

Using Information to Develop a Culture of Customer Centricity sets the stage for understanding the holistic marriage of information, socialization, and process change necessary for transitioning an organization to customer centricity. The book begins with an overview list of 8-10 precepts associated with a business-focused view of the knowledge necessary for developing customer-oriented business processes that lead to excellent customer experiences resulting in increased revenues. Each chapter delves into each precept in more detail.

Zusammenfassung
Focuses on the underlying principles for the design and subsequent development of new anticancer small molecule agents. This book includes several sections on the basic and applied science of cancer drug discovery and features those drugs that are approved for human use and are in the marketplace, as well as those that are still under development.

Inhalt

Introduction - Stephen Neidle

Foreword - Hilary Calvert

Part I. Basic Principles and methodology

Modern cancer drug discovery: integrating targets, technologies and treatments - Paul Workman and
Ian Collins

Pharmacogenomics and personalised medicines in cancer treatment - Wei-Peng Yong, Ross Soo and
Federico Innocenti

Structural biology and anticancer drug design - Puja Pathuri, David Norton, Henriette Willems,
Dominic Tisi and Harren Jhoti

Part II. Drugs in the laboratory and clinic

Temozolomide: from cytotoxic to molecularly-targeted agent - Malcolm Stevens

Temozolomide: patents and the perils of invention - Malcolm Stevens

A new generation of cell-targeted drugs for cancer treatment - Paola B. Arimondo, Nicolas Guilbaud
and Christian Bailly

Inhibition of DNA repair as a therapeutic target - Stephany Veuger and Nicola J Curtin
Inhibitors of tumour angiogenesis - Adrian L. Harris and Daniele G Generali

The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer - Qingzhong Hu and Rolf
W. Hartmann

Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting - Zahid H Siddik

Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel
anticancer agents - Ian R Hardcastle

Targeting altered metabolism - emerging cancer therapeutic strategy - Minsuh Seo, Robert Blake
Crochet and Yong-Hwan Lee

Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway - William A Denny and Gordon W.
Rewcastle

Antibody-drug conjugates delivering DNA cytotoxics - John A Hartley

Inhibition of telomerase: promise, progress and potential pitfalls - Christopher G. Tomlinson, Scott B.
Cohen and Tracy M. Bryan

Targeting B-RAF: the discovery and development of B-RAF inhibitors - Phillip A Harris

Part III. The reality of cancer drugs in the clinic

Failure Modes in Anticancer Drug Discovery and Development - Richard A. Walgren and
Christopher. A. Slapak

Anticancer drug registration and regulation: current challenges and possible solutions - David
Taylor, Erling Donnelly and Silvia Chioato